key: cord-0943424-2i9rgrdt authors: Danchin, Margie; Buttery, Jim title: COVID‐19 vaccine hesitancy: a unique set of challenges date: 2021-10-28 journal: Intern Med J DOI: 10.1111/imj.15599 sha: 2d3652358de4044a0092defc67f5384f55370e3b doc_id: 943424 cord_uid: 2i9rgrdt The global SARS‐CoV‐2 pandemic has seen a revolution in both vaccine development and approval processes enabling life‐saving vaccines to be implemented at record speed. The resultant vaccines, implemented in Australia under provisional licensure, have used vaccine technologies not used before in Australia. Australia and New Zealand, for much of the pandemic, have been spared the high rates of COVID‐19 disease seen elsewhere. Implementing COVID‐19 vaccination programs at an entire adult population level has been a complex, evolving series of programs, with recommendations and strategies responding to community confidence, concerns and rare but potentially severe post‐licensure adverse events. Understanding our diverse community and their concerns, incentivising immunisation, and responding openly to emergent concerns are key components to maintaining community and health care provider confidence in this critical ongoing COVID‐19 vaccine program. This article is protected by copyright. All rights reserved. Additionally, we have been able to capitalise on mRNA and viral vector technology already under development for other pathogens, for COVID-19 vaccine development. (2) Although no vaccine development phases were skipped, many were overlapping and expedited due to huge global investment and collaboration. Regulatory processes utilised emergency-useaccess (EUA) or provisional licensure mechanisms to enable implementation of life saving vaccines after safety follow-up had been completed for all participants two months after their final doses. Nevertheless, despite this triumph of science and the unprecedented collaboration that has delivered effective COVID -19 vaccines in record time, there remains deep distrust for some. The speed of vaccine development and potential implications for vaccine safety continues to impact vaccine acceptance globally. Vaccine acceptance and hesitancy is dynamic and has fluctuated throughout the pandemic, being most affected by surges in COVID-19 disease. (3, 4) In Australia, vaccine acceptance was around 70% prior to vaccine introduction in February 2021 and dipped to 65% at the height of the concerns regarding AstraZeneca and the rare thrombosis and thrombocytopenia syndrome (TTS) vaccine safety signal. It has now reached over 80% as SARS-CoV-2 transmission and COVID-19 cases have increased due to the delta strain. Since implementation in late February 2021, vaccine uptake has primarily been impacted by supply and access factors although hesitancy has continually been highlighted by the media. Using the WHO Behavioural and Social Drivers (BeSD) vaccine acceptance framework, vaccine hesitancy is affected by what people think and feel about vaccines, including attitudes and concerns about vaccine safety, as well as the social processes that underpin acceptance, including provider recommendations and establishing vaccination as the social norm.(5) Practical barriers to vaccination, or access factors, such as time to make or travel to an appointment or waiting time, moderate, but do not drive vaccine hesitancy. Inability to make an appointment or get time off work to attend a vaccine appointment, is not hesitancy, and yet many vulnerable groups with low coverage afflicted by such barriers to vaccination, are falsely labelled as vaccine hesitant. (6) COVID -19 vaccines have posed a unique set of challenges to vaccine acceptance. Vaccine safety, including concerns about common and expected side effects, serious but rare and potential long-term safety issues, have been leading causes of vaccine hesitancy. However, provisional licensure has still required full clinical trial data, albeit with shorter follow-up time periods than are required for full licensure. Even the largest clinical trials are not powered to detect rare adverse events, irrespective of follow-up duration, and these are always monitored for in post-licensure surveillance. Explanation of rare but potentially serious vaccine safety issues such as Thrombosis with Thrombocytopenia (TTS) after some adenoviral vector vaccines and myocarditis and pericarditis post mRNA vaccines have required careful risk-benefit communications on an unprecedented level, according to age and risk profiles. (7, 8) When ATAGI revised their Astra-Zeneca vaccine preferred age recommendations in April and then June in response to developing risk profile understanding, providers and individuals struggled to make sense of the evolving risk and benefit data, and changing recommendations.(9) These further complicated how to interpret and communicate risk according to individual patients' circumstances. (10) This was debated publicly including by health-care professionals, in mainstream media and social media platforms.(11) Furthermore, baseless conspiracy theories have continued to circulate, This article is protected by copyright. All rights reserved. particularly around whether the mRNA vaccines insert genetic material into people's DNA or whether the vaccines contain microchips. (12, 13) Is the vaccine hesitancy observed during the COVID-19 vaccine implementation a different phenomenon than in groups previously described in relation to routine childhood vaccines? (14) While childhood NIP coverage remains high, above 90% across Australia, both positive and punitive incentives have been utilised including linking some family assistance payments and access to early childhood education and care access to immunisation status, through the "No Jab" policies.(15) It remains to be seen how much routine childhood vaccine hesitancy corresponds with COVID-19 vaccine hesitant community members, although the small "refuser" group is likely to substantially overlap. Vaccine coverage in Australia, as of the 30 th September, is 55.1% for 2 doses and 78.5% for 1 dose for all adults over 16 years, with 77.2% of the over 70-year-old group fully vaccinated. NSW are leading, with over 6 million doses given so far, and 28,091,630 doses given nationally. (16) High risk vulnerable groups such as people receiving or working in aged or residential care, people with disabilities, people in Aboriginal and Torres Strait Islander communities and many different cultural groups require targeted and in-reach strategies to improve vaccine coverage. These include strong community engagement, as well as by empowering and working with community, faith, and Indigenous leaders to build trust. Drivers of vaccine hesitancy in many of these groups may include conspiracy theories from countries of origin or historical mistrust in medical and scientific organisations, which may have been exacerbated by public health interventions during the COVID pandemic. Strong provider support with tailored risk-benefit resources, Medicare reimbursement for time spent counselling vaccine hesitant individuals and broad and tailored communication campaigns that address both the direct and indirect benefits of vaccination are needed. Campaigns that focus on the broader benefits of vaccination and harness people's positive motivation to get vaccinated around ability to travel, freedom from lockdowns and school closures, financial security, and social mobility, especially for younger adults who have missed significant life events and freedoms in their lives, will be needed to reach high vaccine coverage.(17) Mandatory vaccination legislation, as well as population vaccinepassports, are now being introduced, requiring careful consideration to ensure equity and ethical issues do not compound disadvantage and unfairly penalise certain groups. (18) COVID-19 and changes in the National Immunisation Program: a unique opportunity to optimise the Australian Immunisation Register (AIR) mRNA vaccines -a new era in vaccinology Intention to vaccinate against COVID-19 in Australia. The Lancet infectious diseases Data for action: achieving high uptake of COVID-19 vaccines: gathering and using data on the behavioural and social drivers of vaccination: a guidebook for immunization programmes and implementing partners: interim guidance. Geneva: World Health Organization The importance of addressing social inequalities and targeting the undecided to promote vaccination against COVID-19 Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. The New England journal of medicine Myocarditis and Pericarditis After Vaccination for COVID-19 ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca Communicating with patients and the public about COVID-19 vaccine safety: recommendations from the Collaboration on Social Science and Immunisation The precautionary principle, the AstraZeneca COVID-19 vaccine and mixed messaging COVID-19 Vaccine Hesitancy and Acceptance in a Cohort of Diverse New Zealanders COVID-19 vaccine rumors and conspiracy theories: The need for cognitive inoculation against misinformation to improve vaccine adherence Parental Immunisation Needs and Attitudes Survey in paediatric hospital clinics and community maternal and child health centres in Melbourne Imposing penalties for vaccine rejection requires strong scrutiny Australian Government Operation COVID Shield. COVID-19 Vaccine Roll-out 01 October 2021: Australia's COVID-19 Vaccine Roadmap Incentives can spur COVID-19 vaccination uptake Policy considerations for mandatory COVID-19 vaccination from the Collaboration on Social Science in Immunisation. The Medical journal of Australia This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.